Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

NCT00716456 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: erlotinib with cetuximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]